FGFR3 mutations primarily affect bone growth, but the same molecular mechanisms—dysregulated FGFR3 signaling and downstream pathways—can also stimulate epidermal proliferation, distinguishing it from insulin resistance–associated AN [1, 2]. The gene discussed is FGFR3; the disease is Insulin resistance.